033270.KO United Pharm
- Market cap
- KRW 256B
- P/E
- 12.6x
- P/B
- 0.51x
- ROE
- 20.8%
- Dividend yield
- 2.59%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 033270.KO undervalued?
Graham number033270.KO trades 46.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
United Pharm fundamental analysis
No fundamental analysis for United Pharm yet.
United Pharm stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About United Pharm
Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to approximately 40 countries. Korea United Pharm Inc. was founded in 1987 and is head…
Full company profileUnited Pharm financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
United Pharm annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 177B | 197B | 212B | 221B | 216B | 221B | 263B | 279B | 289B | 289B | 302B |
| Gross Profit | 96.8B | 112B | 125B | 129B | 125B | 123B | 145B | 159B | 164B | 161B | 167B |
| Operating Income | 27.1B | 31.7B | 37.8B | 35.0B | 40.1B | 33.2B | 48.2B | 55.3B | 33.5B | 50.1B | 49.7B |
| EBITDA | - | 36.4B | 47.9B | 46.5B | 44.7B | 47.7B | 63.2B | 71.8B | 57.8B | 61.6B | 129B |
| Net Income | 19.5B | 27.9B | 31.7B | 30.9B | 26.6B | 28.6B | 45.3B | 48.3B | 32.5B | 38.3B | 103B |
| EPS | - | 1,882 | 2,139 | 2,085 | 1,793 | 1,930 | 3,078 | 3,301 | 2,206 | 2,653 | 6,518 |
| Balance Sheet | |||||||||||
| Total Assets | 234B | 266B | 302B | 331B | 353B | 380B | 418B | 469B | 474B | 519B | 571B |
| Total Liabilities | 56.8B | 64.1B | 73.5B | 76.1B | 76.5B | 79.3B | 80.0B | 90.2B | 67.7B | 64.9B | 73.6B |
| Shareholders' Equity | 177B | 202B | 228B | 255B | 277B | 301B | 338B | 379B | 406B | 455B | 497B |
| Cash & Short-term Investments | 18.4B | 10.0B | 24.3B | 40.0B | 40.5B | 60.8B | 26.9B | 23.9B | 33.7B | 40.3B | 41.7B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 30.0B | 27.7B | 36.9B | 38.2B | 37.0B | 44.1B | 63.8B | 49.8B | 26.8B | 51.1B | 98.6B |
| Capital Expenditure | 13.3B | 27.6B | 17.3B | 19.8B | 12.5B | 12.8B | 24.2B | 31.3B | 21.2B | 25.1B | 53.6B |
| Free Cash Flow | - | 90.8M | 19.5B | 18.4B | 24.4B | 31.3B | 39.6B | 18.5B | 5.57B | 26.0B | 44.9B |
| Ratios | |||||||||||
| ROE | 11.0% | 13.8% | 13.9% | 12.1% | 9.6% | 9.5% | 13.4% | 12.7% | 8.0% | 8.4% | 20.8% |
| ROA | 8.3% | 10.5% | 10.5% | 9.3% | 7.5% | 7.5% | 10.8% | 10.3% | 6.8% | 7.4% | 18.1% |
| Net Profit Margin | 11.0% | 14.1% | 14.9% | 14.0% | 12.3% | 13.0% | 17.2% | 17.3% | 11.2% | 13.3% | 34.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
United Pharm dividends
- Dividend yield
- 2.59%
- Forward dividend
- 610.00 KRW
- Payout ratio
- 17.3%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 6.62B | 458 | 17.3% |
| 2024 | KRW 6.14B | 417 | 18.9% |
| 2023 | KRW 5.88B | 402 | 12.2% |
| 2022 | KRW 5.49B | 373 | 12.1% |
| 2021 | KRW 5.20B | 350 | 18.1% |
| 2020 | KRW 4.89B | 330 | 18.4% |
| 2019 | KRW 4.89B | 329 | 15.8% |
| 2018 | KRW 4.44B | 300 | 14.0% |
| 2017 | KRW 3.70B | 250 | 13.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.02:1 on Jan 20, 2014.
Who owns United Pharm
- Insiders 41.66%
- Institutions 2.60%
- Public & others 55.74%
- Shares outstanding 15.9M
- Free float 8.43M
United Pharm company profile
- Company name
- United Pharm
- Ticker
- 033270.KO
- ISIN
- KR7033270000
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- Nonhyeon-ro 121street 22, Seoul, South Korea
- Phone
- 82 2 512 9981
- Website
- kup.co.kr
About United Pharm
Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to approximately 40 countries. Korea United Pharm Inc. was founded in 1987 and is headquartered in Seoul, South Korea.
United Pharm management
1- Mr. Duk-Young KangChief Executive Officer · born 1947